JP2020514419A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020514419A5 JP2020514419A5 JP2020500010A JP2020500010A JP2020514419A5 JP 2020514419 A5 JP2020514419 A5 JP 2020514419A5 JP 2020500010 A JP2020500010 A JP 2020500010A JP 2020500010 A JP2020500010 A JP 2020500010A JP 2020514419 A5 JP2020514419 A5 JP 2020514419A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- alkyl
- substituted
- alkenyl
- halogen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 125000000217 alkyl group Chemical group 0.000 claims 31
- 125000001424 substituent group Chemical group 0.000 claims 23
- 229910052736 halogen Inorganic materials 0.000 claims 22
- 150000002367 halogens Chemical class 0.000 claims 22
- 150000001875 compounds Chemical class 0.000 claims 20
- 125000000304 alkynyl group Chemical group 0.000 claims 19
- 125000006374 C2-C10 alkenyl group Chemical group 0.000 claims 18
- 125000000623 heterocyclic group Chemical group 0.000 claims 17
- 206010028980 Neoplasm Diseases 0.000 claims 16
- 229910052739 hydrogen Inorganic materials 0.000 claims 15
- 239000001257 hydrogen Substances 0.000 claims 15
- 150000003839 salts Chemical class 0.000 claims 15
- 229910052799 carbon Inorganic materials 0.000 claims 14
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 10
- 125000002618 bicyclic heterocycle group Chemical group 0.000 claims 10
- 150000002431 hydrogen Chemical class 0.000 claims 10
- 201000011510 cancer Diseases 0.000 claims 8
- 230000005494 condensation Effects 0.000 claims 8
- 238000009833 condensation Methods 0.000 claims 8
- KZNICNPSHKQLFF-UHFFFAOYSA-N succinimide Chemical group O=C1CCC(=O)N1 KZNICNPSHKQLFF-UHFFFAOYSA-N 0.000 claims 8
- 239000003814 drug Substances 0.000 claims 7
- 239000000427 antigen Substances 0.000 claims 6
- 102000036639 antigens Human genes 0.000 claims 6
- 108091007433 antigens Proteins 0.000 claims 6
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 5
- -1 R 21 Chemical compound 0.000 claims 5
- 125000002947 alkylene group Chemical group 0.000 claims 5
- 125000002619 bicyclic group Chemical group 0.000 claims 5
- 125000001188 haloalkyl group Chemical group 0.000 claims 5
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims 4
- 125000005647 linker group Chemical group 0.000 claims 4
- 239000008194 pharmaceutical composition Substances 0.000 claims 4
- 206010018338 Glioma Diseases 0.000 claims 3
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 claims 3
- 206010025323 Lymphomas Diseases 0.000 claims 3
- 201000010099 disease Diseases 0.000 claims 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 3
- 229910052757 nitrogen Inorganic materials 0.000 claims 3
- 201000008968 osteosarcoma Diseases 0.000 claims 3
- 229960002087 pertuzumab Drugs 0.000 claims 3
- 210000004500 stellate cell Anatomy 0.000 claims 3
- 210000000115 thoracic cavity Anatomy 0.000 claims 3
- UWYZHKAOTLEWKK-UHFFFAOYSA-N 1,2,3,4-tetrahydroisoquinoline Chemical compound C1=CC=C2CNCCC2=C1 UWYZHKAOTLEWKK-UHFFFAOYSA-N 0.000 claims 2
- LBUJPTNKIBCYBY-UHFFFAOYSA-N 1,2,3,4-tetrahydroquinoline Chemical compound C1=CC=C2CCCNC2=C1 LBUJPTNKIBCYBY-UHFFFAOYSA-N 0.000 claims 2
- NFGXHKASABOEEW-UHFFFAOYSA-N 1-methylethyl 11-methoxy-3,7,11-trimethyl-2,4-dodecadienoate Chemical compound COC(C)(C)CCCC(C)CC=CC(C)=CC(=O)OC(C)C NFGXHKASABOEEW-UHFFFAOYSA-N 0.000 claims 2
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 claims 2
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims 2
- 208000003200 Adenoma Diseases 0.000 claims 2
- 206010001233 Adenoma benign Diseases 0.000 claims 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 2
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 claims 2
- 208000003174 Brain Neoplasms Diseases 0.000 claims 2
- 206010006187 Breast cancer Diseases 0.000 claims 2
- 208000026310 Breast neoplasm Diseases 0.000 claims 2
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims 2
- 206010008342 Cervix carcinoma Diseases 0.000 claims 2
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 claims 2
- 206010009944 Colon cancer Diseases 0.000 claims 2
- 208000032612 Glial tumor Diseases 0.000 claims 2
- 208000017604 Hodgkin disease Diseases 0.000 claims 2
- 208000021519 Hodgkin lymphoma Diseases 0.000 claims 2
- 208000010747 Hodgkins lymphoma Diseases 0.000 claims 2
- 101100368708 Homo sapiens TACSTD2 gene Proteins 0.000 claims 2
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 2
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims 2
- 239000004472 Lysine Substances 0.000 claims 2
- PEEHTFAAVSWFBL-UHFFFAOYSA-N Maleimide Chemical compound O=C1NC(=O)C=C1 PEEHTFAAVSWFBL-UHFFFAOYSA-N 0.000 claims 2
- 208000006644 Malignant Fibrous Histiocytoma Diseases 0.000 claims 2
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 claims 2
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims 2
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims 2
- 206010038389 Renal cancer Diseases 0.000 claims 2
- 208000006265 Renal cell carcinoma Diseases 0.000 claims 2
- 206010039491 Sarcoma Diseases 0.000 claims 2
- 208000000453 Skin Neoplasms Diseases 0.000 claims 2
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 2
- 208000031673 T-Cell Cutaneous Lymphoma Diseases 0.000 claims 2
- 208000024770 Thyroid neoplasm Diseases 0.000 claims 2
- 208000015778 Undifferentiated pleomorphic sarcoma Diseases 0.000 claims 2
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims 2
- 208000009956 adenocarcinoma Diseases 0.000 claims 2
- 125000003275 alpha amino acid group Chemical group 0.000 claims 2
- 210000004027 cell Anatomy 0.000 claims 2
- 201000010881 cervical cancer Diseases 0.000 claims 2
- 208000029742 colonic neoplasm Diseases 0.000 claims 2
- 201000007241 cutaneous T cell lymphoma Diseases 0.000 claims 2
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 claims 2
- 229940079593 drug Drugs 0.000 claims 2
- 239000012634 fragment Substances 0.000 claims 2
- 206010017758 gastric cancer Diseases 0.000 claims 2
- 201000009277 hairy cell leukemia Diseases 0.000 claims 2
- 102000051957 human ERBB2 Human genes 0.000 claims 2
- 102000046001 human TACSTD2 Human genes 0.000 claims 2
- PQNFLJBBNBOBRQ-UHFFFAOYSA-N indane Chemical class C1=CC=C2CCCC2=C1 PQNFLJBBNBOBRQ-UHFFFAOYSA-N 0.000 claims 2
- 201000010982 kidney cancer Diseases 0.000 claims 2
- 208000032839 leukemia Diseases 0.000 claims 2
- 201000005202 lung cancer Diseases 0.000 claims 2
- 208000020816 lung neoplasm Diseases 0.000 claims 2
- 201000001441 melanoma Diseases 0.000 claims 2
- 201000005962 mycosis fungoides Diseases 0.000 claims 2
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 2
- 125000004430 oxygen atom Chemical group O* 0.000 claims 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 2
- 208000025638 primary cutaneous T-cell non-Hodgkin lymphoma Diseases 0.000 claims 2
- 108090000765 processed proteins & peptides Proteins 0.000 claims 2
- 230000002062 proliferating effect Effects 0.000 claims 2
- 201000000849 skin cancer Diseases 0.000 claims 2
- 201000011549 stomach cancer Diseases 0.000 claims 2
- 208000011580 syndromic disease Diseases 0.000 claims 2
- 201000002510 thyroid cancer Diseases 0.000 claims 2
- 229960000575 trastuzumab Drugs 0.000 claims 2
- AGGWFDNPHKLBBV-YUMQZZPRSA-N (2s)-2-[[(2s)-2-amino-3-methylbutanoyl]amino]-5-(carbamoylamino)pentanoic acid Chemical compound CC(C)[C@H](N)C(=O)N[C@H](C(O)=O)CCCNC(N)=O AGGWFDNPHKLBBV-YUMQZZPRSA-N 0.000 claims 1
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 claims 1
- FGFBEHFJSQBISW-UHFFFAOYSA-N 1h-cyclopenta[b]pyridine Chemical compound C1=CNC2=CC=CC2=C1 FGFBEHFJSQBISW-UHFFFAOYSA-N 0.000 claims 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 1
- 208000002008 AIDS-Related Lymphoma Diseases 0.000 claims 1
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 claims 1
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims 1
- 208000005440 Basal Cell Neoplasms Diseases 0.000 claims 1
- 206010004146 Basal cell carcinoma Diseases 0.000 claims 1
- 206010061692 Benign muscle neoplasm Diseases 0.000 claims 1
- 206010005003 Bladder cancer Diseases 0.000 claims 1
- 208000018084 Bone neoplasm Diseases 0.000 claims 1
- 206010006143 Brain stem glioma Diseases 0.000 claims 1
- 101100240516 Caenorhabditis elegans nhr-10 gene Proteins 0.000 claims 1
- 201000009030 Carcinoma Diseases 0.000 claims 1
- 208000005243 Chondrosarcoma Diseases 0.000 claims 1
- 206010014733 Endometrial cancer Diseases 0.000 claims 1
- 206010014759 Endometrial neoplasm Diseases 0.000 claims 1
- 102000004190 Enzymes Human genes 0.000 claims 1
- 108090000790 Enzymes Proteins 0.000 claims 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims 1
- 208000006168 Ewing Sarcoma Diseases 0.000 claims 1
- 201000003741 Gastrointestinal carcinoma Diseases 0.000 claims 1
- 208000019758 Hypergammaglobulinemia Diseases 0.000 claims 1
- 206010021042 Hypopharyngeal cancer Diseases 0.000 claims 1
- 206010056305 Hypopharyngeal neoplasm Diseases 0.000 claims 1
- 206010061252 Intraocular melanoma Diseases 0.000 claims 1
- 208000007766 Kaposi sarcoma Diseases 0.000 claims 1
- 206010023825 Laryngeal cancer Diseases 0.000 claims 1
- 206010062038 Lip neoplasm Diseases 0.000 claims 1
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 claims 1
- 206010025312 Lymphoma AIDS related Diseases 0.000 claims 1
- 206010025557 Malignant fibrous histiocytoma of bone Diseases 0.000 claims 1
- 206010025997 Malignant neoplasm of islets of Langerhans Diseases 0.000 claims 1
- 208000002030 Merkel cell carcinoma Diseases 0.000 claims 1
- 208000003445 Mouth Neoplasms Diseases 0.000 claims 1
- 208000034578 Multiple myelomas Diseases 0.000 claims 1
- 206010028570 Myelopathy Diseases 0.000 claims 1
- 201000007224 Myeloproliferative neoplasm Diseases 0.000 claims 1
- 201000004458 Myoma Diseases 0.000 claims 1
- 208000001894 Nasopharyngeal Neoplasms Diseases 0.000 claims 1
- 206010061306 Nasopharyngeal cancer Diseases 0.000 claims 1
- 206010029260 Neuroblastoma Diseases 0.000 claims 1
- 206010029266 Neuroendocrine carcinoma of the skin Diseases 0.000 claims 1
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims 1
- 208000010505 Nose Neoplasms Diseases 0.000 claims 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims 1
- 206010031096 Oropharyngeal cancer Diseases 0.000 claims 1
- 206010057444 Oropharyngeal neoplasm Diseases 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 208000000821 Parathyroid Neoplasms Diseases 0.000 claims 1
- 208000009565 Pharyngeal Neoplasms Diseases 0.000 claims 1
- 206010034811 Pharyngeal cancer Diseases 0.000 claims 1
- 208000007913 Pituitary Neoplasms Diseases 0.000 claims 1
- 201000005746 Pituitary adenoma Diseases 0.000 claims 1
- 206010061538 Pituitary tumour benign Diseases 0.000 claims 1
- 208000033014 Plasma cell tumor Diseases 0.000 claims 1
- 208000007452 Plasmacytoma Diseases 0.000 claims 1
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 201000008183 Pulmonary blastoma Diseases 0.000 claims 1
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 claims 1
- 208000015634 Rectal Neoplasms Diseases 0.000 claims 1
- 201000000582 Retinoblastoma Diseases 0.000 claims 1
- 206010041067 Small cell lung cancer Diseases 0.000 claims 1
- 208000021712 Soft tissue sarcoma Diseases 0.000 claims 1
- 208000024313 Testicular Neoplasms Diseases 0.000 claims 1
- 206010057644 Testis cancer Diseases 0.000 claims 1
- 206010043515 Throat cancer Diseases 0.000 claims 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 1
- 208000002495 Uterine Neoplasms Diseases 0.000 claims 1
- 201000005969 Uveal melanoma Diseases 0.000 claims 1
- HSRXSKHRSXRCFC-WDSKDSINSA-N Val-Ala Chemical compound CC(C)[C@H](N)C(=O)N[C@@H](C)C(O)=O HSRXSKHRSXRCFC-WDSKDSINSA-N 0.000 claims 1
- 208000033559 Waldenström macroglobulinemia Diseases 0.000 claims 1
- 208000008383 Wilms tumor Diseases 0.000 claims 1
- 150000001345 alkine derivatives Chemical class 0.000 claims 1
- 210000000941 bile Anatomy 0.000 claims 1
- 210000000013 bile duct Anatomy 0.000 claims 1
- 210000000988 bone and bone Anatomy 0.000 claims 1
- 201000002143 bronchus adenoma Diseases 0.000 claims 1
- 125000002837 carbocyclic group Chemical group 0.000 claims 1
- 150000001721 carbon Chemical group 0.000 claims 1
- 230000002490 cerebral effect Effects 0.000 claims 1
- 210000004720 cerebrum Anatomy 0.000 claims 1
- 230000001684 chronic effect Effects 0.000 claims 1
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 claims 1
- 208000017763 cutaneous neuroendocrine carcinoma Diseases 0.000 claims 1
- 201000004101 esophageal cancer Diseases 0.000 claims 1
- 208000024519 eye neoplasm Diseases 0.000 claims 1
- 201000010536 head and neck cancer Diseases 0.000 claims 1
- 208000014829 head and neck neoplasm Diseases 0.000 claims 1
- 201000010235 heart cancer Diseases 0.000 claims 1
- 208000024348 heart neoplasm Diseases 0.000 claims 1
- 125000004474 heteroalkylene group Chemical group 0.000 claims 1
- 208000029824 high grade glioma Diseases 0.000 claims 1
- 201000006866 hypopharynx cancer Diseases 0.000 claims 1
- 230000001096 hypoplastic effect Effects 0.000 claims 1
- 230000002267 hypothalamic effect Effects 0.000 claims 1
- 201000002313 intestinal cancer Diseases 0.000 claims 1
- 238000001990 intravenous administration Methods 0.000 claims 1
- 210000004153 islets of langerhan Anatomy 0.000 claims 1
- 206010023841 laryngeal neoplasm Diseases 0.000 claims 1
- 208000012987 lip and oral cavity carcinoma Diseases 0.000 claims 1
- 201000006721 lip cancer Diseases 0.000 claims 1
- 206010024627 liposarcoma Diseases 0.000 claims 1
- 210000002751 lymph Anatomy 0.000 claims 1
- 230000002132 lysosomal effect Effects 0.000 claims 1
- 201000000564 macroglobulinemia Diseases 0.000 claims 1
- 201000011614 malignant glioma Diseases 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 208000026045 malignant tumor of parathyroid gland Diseases 0.000 claims 1
- 230000001394 metastastic effect Effects 0.000 claims 1
- 206010061289 metastatic neoplasm Diseases 0.000 claims 1
- 201000000050 myeloid neoplasm Diseases 0.000 claims 1
- 208000037830 nasal cancer Diseases 0.000 claims 1
- 230000009826 neoplastic cell growth Effects 0.000 claims 1
- 201000008026 nephroblastoma Diseases 0.000 claims 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims 1
- 201000008106 ocular cancer Diseases 0.000 claims 1
- 201000002575 ocular melanoma Diseases 0.000 claims 1
- 201000006958 oropharynx cancer Diseases 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 1
- ZNSWGHZWUUFFKV-UHFFFAOYSA-N piperidine;pyridine Chemical class C1CCNCC1.C1=CC=NC=C1 ZNSWGHZWUUFFKV-UHFFFAOYSA-N 0.000 claims 1
- 208000021310 pituitary gland adenoma Diseases 0.000 claims 1
- 208000010626 plasma cell neoplasm Diseases 0.000 claims 1
- 210000004180 plasmocyte Anatomy 0.000 claims 1
- 102000004196 processed proteins & peptides Human genes 0.000 claims 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 claims 1
- 206010038038 rectal cancer Diseases 0.000 claims 1
- 201000001275 rectum cancer Diseases 0.000 claims 1
- 229920006395 saturated elastomer Polymers 0.000 claims 1
- 208000000587 small cell lung carcinoma Diseases 0.000 claims 1
- 210000004872 soft tissue Anatomy 0.000 claims 1
- 206010041823 squamous cell carcinoma Diseases 0.000 claims 1
- 238000007920 subcutaneous administration Methods 0.000 claims 1
- 201000003120 testicular cancer Diseases 0.000 claims 1
- CXWXQJXEFPUFDZ-UHFFFAOYSA-N tetralin Chemical class C1=CC=C2CCCCC2=C1 CXWXQJXEFPUFDZ-UHFFFAOYSA-N 0.000 claims 1
- 230000007704 transition Effects 0.000 claims 1
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims 1
- 208000018417 undifferentiated high grade pleomorphic sarcoma of bone Diseases 0.000 claims 1
- 201000005112 urinary bladder cancer Diseases 0.000 claims 1
- 210000001635 urinary tract Anatomy 0.000 claims 1
- 206010046766 uterine cancer Diseases 0.000 claims 1
- 206010046885 vaginal cancer Diseases 0.000 claims 1
- 208000013139 vaginal neoplasm Diseases 0.000 claims 1
- 230000000007 visual effect Effects 0.000 claims 1
- 0 CCCN(CCC)C(C(CC(N)=Nc1c2)=Cc1ccc2C(Nc1cccc(C(*)=O)c1)=O)=O Chemical compound CCCN(CCC)C(C(CC(N)=Nc1c2)=Cc1ccc2C(Nc1cccc(C(*)=O)c1)=O)=O 0.000 description 3
- QVSQMRFWFRSZMS-UHFFFAOYSA-N CCCN(CCC)C(C(CC(N)=Nc1c2)=Cc1ccc2C(Nc(cc1)ccc1N(CC1)CCC1O)=O)=O Chemical compound CCCN(CCC)C(C(CC(N)=Nc1c2)=Cc1ccc2C(Nc(cc1)ccc1N(CC1)CCC1O)=O)=O QVSQMRFWFRSZMS-UHFFFAOYSA-N 0.000 description 1
- APUDKOSUPNXOIR-UHFFFAOYSA-N CCCN(CCC)C(C(CC(N)=Nc1c2)=Cc1ccc2C(Nc(cc1)ccc1N(CCC1)CC1O)=O)=O Chemical compound CCCN(CCC)C(C(CC(N)=Nc1c2)=Cc1ccc2C(Nc(cc1)ccc1N(CCC1)CC1O)=O)=O APUDKOSUPNXOIR-UHFFFAOYSA-N 0.000 description 1
- JGQSALJLSDESHS-UHFFFAOYSA-N CCCN(CCC)C1OC1C(CC(N)=Nc1c2)=Cc1ccc2C(Nc(cc1)cnc1N(CCC1)CC1NOC(c1ccccc1)=O)=O Chemical compound CCCN(CCC)C1OC1C(CC(N)=Nc1c2)=Cc1ccc2C(Nc(cc1)cnc1N(CCC1)CC1NOC(c1ccccc1)=O)=O JGQSALJLSDESHS-UHFFFAOYSA-N 0.000 description 1
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762471886P | 2017-03-15 | 2017-03-15 | |
| US62/471,886 | 2017-03-15 | ||
| US201762573630P | 2017-10-17 | 2017-10-17 | |
| US62/573,630 | 2017-10-17 | ||
| US201862622780P | 2018-01-26 | 2018-01-26 | |
| US62/622,780 | 2018-01-26 | ||
| PCT/US2018/022510 WO2018170179A1 (en) | 2017-03-15 | 2018-03-14 | Benzazepine compounds, conjugates, and uses thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2020514419A JP2020514419A (ja) | 2020-05-21 |
| JP2020514419A5 true JP2020514419A5 (sl) | 2021-04-30 |
Family
ID=63523998
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020500010A Ceased JP2020514419A (ja) | 2017-03-15 | 2018-03-14 | ベンズアゼピン化合物、そのコンジュゲート及び使用 |
Country Status (16)
| Country | Link |
|---|---|
| US (5) | US10239862B2 (sl) |
| EP (2) | EP3595668B1 (sl) |
| JP (1) | JP2020514419A (sl) |
| KR (1) | KR20200031560A (sl) |
| CN (1) | CN110612104A (sl) |
| AU (1) | AU2018236272B2 (sl) |
| BR (1) | BR112019019116A2 (sl) |
| CA (1) | CA3055652A1 (sl) |
| DK (1) | DK3595668T3 (sl) |
| ES (1) | ES2894731T3 (sl) |
| HU (1) | HUE056427T2 (sl) |
| IL (1) | IL269283B2 (sl) |
| MX (1) | MX2019010804A (sl) |
| PT (1) | PT3595668T (sl) |
| SG (5) | SG11201908131RA (sl) |
| WO (1) | WO2018170179A1 (sl) |
Families Citing this family (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3464274B1 (en) * | 2016-05-23 | 2020-05-27 | H. Hoffnabb-La Roche Ag | Benzazepine dicarboxamide compounds with secondary amide function |
| WO2018009916A1 (en) | 2016-07-07 | 2018-01-11 | The Board Of Trustees Of The Leland Stanford Junior University | Antibody adjuvant conjugates |
| EP3595668B1 (en) | 2017-03-15 | 2021-07-21 | Silverback Therapeutics, Inc. | Benzazepine compounds, conjugates, and uses thereof |
| KR20210025522A (ko) | 2018-06-25 | 2021-03-09 | 유니버시티 오브 워싱톤 | 강력하고 선택적인 인터루킨 모방체의 드 노보 디자인 |
| EP3849615A1 (en) * | 2018-09-12 | 2021-07-21 | Silverback Therapeutics, Inc. | Compositions for the treatment of disease with immune stimulatory conjugates |
| WO2020056198A2 (en) * | 2018-09-12 | 2020-03-19 | Silverback Therapeutics, Inc. | Substituted benzazepine compounds, conjugates, and uses thereof |
| WO2020056194A1 (en) * | 2018-09-12 | 2020-03-19 | Silverback Therapeutics, Inc. | Benzazepine compounds, conjugates, and uses thereof |
| EP3883956A1 (en) | 2018-11-20 | 2021-09-29 | University of Washington | Split interleukin mimetics and their use |
| WO2020190725A1 (en) | 2019-03-15 | 2020-09-24 | Bolt Biotherapeutics, Inc. | Immunoconjugates targeting her2 |
| WO2020227538A1 (en) * | 2019-05-08 | 2020-11-12 | Memorial Sloan Kettering Cancer Center | Humanized antibodies to mucin-16 and methods of use thereof |
| EP3983080A1 (en) * | 2019-06-13 | 2022-04-20 | Bolt Biotherapeutics, Inc. | Macromolecule-supported aminobenzazepine compounds |
| CA3142887A1 (en) * | 2019-06-13 | 2020-12-17 | Bolt Biotherapeutics, Inc. | Aminobenzazepine compounds, immunoconjugates, and uses thereof |
| US20220249685A1 (en) | 2019-06-19 | 2022-08-11 | Silverback Therapeutics, Inc. | Anti-mesothelin antibodies and immunoconjugates thereof |
| CN114667134A (zh) * | 2019-08-15 | 2022-06-24 | 希沃尔拜克治疗公司 | 苯并氮杂䓬缀合物的制剂及其用途 |
| WO2021067242A1 (en) * | 2019-09-30 | 2021-04-08 | Bolt Biotherapeutics, Inc. | Amide-linked, aminobenzazepine immunoconjugates, and uses thereof |
| AU2020358726A1 (en) * | 2019-10-01 | 2022-04-07 | Silverback Therapeutics, Inc. | Combination therapy with immune stimulatory conjugates |
| WO2021072330A1 (en) | 2019-10-09 | 2021-04-15 | Silverback Therapeutics, Inc. | Galnac-tgfbr1 inhibitor conjugates for the treatment of liver diseases |
| US20210130473A1 (en) | 2019-10-09 | 2021-05-06 | Silverback Therapeutics, Inc. | TGFßR1 INHIBITOR-ASGR ANTIBODY CONJUGATES AND USES THEREOF |
| US11554999B2 (en) | 2019-11-15 | 2023-01-17 | Goodrich Corporation | Inflation systems for evacuation slides and life rafts |
| EP4106819A1 (en) | 2020-02-21 | 2022-12-28 | Silverback Therapeutics, Inc. | Nectin-4 antibody conjugates and uses thereof |
| US20230340071A1 (en) | 2020-03-16 | 2023-10-26 | Neoleukin Therapeutics, Inc. | Interleukin-2 Receptor Beta (IL-2RB) Binding Polypeptides |
| CA3173628A1 (en) | 2020-04-07 | 2021-10-14 | Thomas Linsky | De novo protein decoys of angiotensin-converting enzyme 2 (ace2) |
| CN116209678A (zh) | 2020-07-01 | 2023-06-02 | 安尔士制药公司 | 抗asgr1抗体缀合物及其用途 |
| WO2022031680A1 (en) * | 2020-08-04 | 2022-02-10 | Exelixis, Inc. | Cd47 binding agents and uses thereof |
| WO2022031695A1 (en) * | 2020-08-04 | 2022-02-10 | Exelixis, Inc. | Pd-l1 binding agents and uses thereof |
| IL300316A (en) * | 2020-08-13 | 2023-04-01 | Bolt Biotherapeutics Inc | Immune conjugates of pyrazolozapines and their uses |
| US20220195066A1 (en) * | 2020-12-11 | 2022-06-23 | Bolt Biotherapeutics, Inc. | Anti-cea immunoconjugates, and uses thereof |
| CN117042806A (zh) * | 2021-03-08 | 2023-11-10 | 启德医药科技（苏州）有限公司 | 抗体-免疫激动剂缀合物及其应用 |
| JP2024518709A (ja) | 2021-04-10 | 2024-05-02 | プロファウンドバイオ ユーエス カンパニー | Ｆｏｌｒ１結合剤、そのコンジュゲートおよびこれを使用する方法 |
| AU2022262644A1 (en) | 2021-04-23 | 2023-11-09 | Profoundbio Us Co. | Anti-cd70 antibodies, conjugates thereof and methods of using the same |
| WO2022242724A1 (zh) | 2021-05-19 | 2022-11-24 | 上海迪诺医药科技有限公司 | 一种含氮化合物、含其的偶联物及其应用 |
| TW202320857A (zh) | 2021-07-06 | 2023-06-01 | 美商普方生物製藥美國公司 | 連接子、藥物連接子及其結合物及其使用方法 |
| WO2023044318A2 (en) | 2021-09-15 | 2023-03-23 | Neoleukin Therapeutics, Inc. | Interleukin-2 receptor βeta (il-2rβ) binding polypeptides |
| WO2023154318A1 (en) * | 2022-02-09 | 2023-08-17 | Bolt Biotherapeutics, Inc. | Anti-tr0p2, aminobenzazepine immunoconjugates, and uses thereof |
| WO2024067841A1 (zh) * | 2022-09-30 | 2024-04-04 | 上海迪诺医药科技有限公司 | 苯并氮杂卓衍生物、含其的偶联物及其应用 |
Family Cites Families (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1995026325A2 (en) | 1994-03-25 | 1995-10-05 | Isotechnika Inc. | Enhancement of the efficacy of drugs by deuteration |
| US6334997B1 (en) | 1994-03-25 | 2002-01-01 | Isotechnika, Inc. | Method of using deuterated calcium channel blockers |
| US6130217A (en) * | 1995-09-20 | 2000-10-10 | Pfizer Inc | Compounds enhancing antitumor activity of other cytotoxic agents |
| DK0825186T3 (da) | 1996-08-16 | 2002-07-22 | Pfizer | 2-aminobenzazepinderivater og deres anvendelse til behandling af immunosuppression |
| US20040141983A1 (en) | 1999-03-15 | 2004-07-22 | Protein Design Labs, Inc. | Compositions against cancer antigen LIV-1 and uses thereof |
| US6953787B2 (en) * | 2002-04-12 | 2005-10-11 | Arena Pharmaceuticals, Inc. | 5HT2C receptor modulators |
| US7585326B2 (en) | 2004-08-06 | 2009-09-08 | Spinalmotion, Inc. | Methods and apparatus for intervertebral disc prosthesis insertion |
| KR101888321B1 (ko) | 2005-07-01 | 2018-08-13 | 이. 알. 스퀴부 앤드 선즈, 엘.엘.씨. | 예정 사멸 리간드 1 (피디-엘1)에 대한 인간 모노클로날 항체 |
| TW201402124A (zh) | 2005-08-19 | 2014-01-16 | Array Biopharma Inc | 作為類鐸受體（ｔｏｌｌ-ｌｉｋｅ ｒｅｃｅｐｔｏｒ）調節劑之８-經取代苯并氮雜呯 |
| AU2010284240B2 (en) | 2009-08-18 | 2016-11-10 | Array Biopharma, Inc. | Substituted benzoazepines as Toll-like receptor modulators |
| AU2010284241B2 (en) | 2009-08-18 | 2016-11-10 | Array Biopharma, Inc. | Substituted benzoazepines as Toll-like receptor modulators |
| JP5837567B2 (ja) | 2010-03-26 | 2015-12-24 | メモリアル スローン−ケタリング キャンサー センター | Ｍｕｃ１６に対する抗体およびその使用方法 |
| US9228026B2 (en) | 2010-12-06 | 2016-01-05 | Seattle Genetics, Inc. | Humanized antibodies to LIV-1 and use of same to treat cancer |
| EP2663550B1 (en) | 2011-01-12 | 2016-12-14 | VentiRx Pharmaceuticals, Inc. | Substituted benzoazepines as toll-like receptor modulators |
| WO2012097177A2 (en) | 2011-01-12 | 2012-07-19 | Ventirx Pharmaceuticals, Inc. | Substituted benzoazepines as toll-like receptor modulators |
| US9034336B2 (en) * | 2011-08-30 | 2015-05-19 | Regents Of The University Of Minnesota | Immunomodulators and immunomodulator conjugates |
| US9504756B2 (en) | 2012-05-15 | 2016-11-29 | Seattle Genetics, Inc. | Self-stabilizing linker conjugates |
| CN112587671A (zh) | 2012-07-18 | 2021-04-02 | 博笛生物科技有限公司 | 癌症的靶向免疫治疗 |
| RU2669807C2 (ru) * | 2014-01-27 | 2018-10-16 | Пфайзер Инк. | Бифункциональные цитотоксические агенты |
| RS59799B1 (sr) | 2014-04-25 | 2020-02-28 | Pf Medicament | Konjugat antitelo - lek i njegova upotreba u lečenju kancera |
| CN112546230A (zh) | 2014-07-09 | 2021-03-26 | 博笛生物科技有限公司 | 用于治疗癌症的联合治疗组合物和联合治疗方法 |
| SG11201704791WA (en) | 2014-12-16 | 2017-07-28 | Celgene Corp | Solid forms comprising (1e, 4e)-2-amino-n,n-dipropyl-8-(4-(pyrrolidine-1-carbonyl)phenyl)-3h-benzo[b]azepine-4-carboxamide, compositions thereof, and uses thereof |
| EP3233835B1 (en) | 2014-12-18 | 2019-01-23 | F.Hoffmann-La Roche Ag | Benzazepine sulfonamide compounds |
| JP6676058B2 (ja) | 2015-01-14 | 2020-04-08 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | ヘテロアリーレン架橋したベンゾジアゼピン二量体、そのコンジュゲート、ならびに製造および使用方法 |
| SI3265458T1 (sl) | 2015-03-06 | 2019-03-29 | F. Hoffmann-La Roche Ag | Benzazepin dikarboksamidne spojine |
| US9943416B2 (en) | 2015-03-10 | 2018-04-17 | Simplify Medical Pty Limited | Intervertebral spacer that dynamically promotes bone growth |
| EP4071131A1 (en) | 2016-04-13 | 2022-10-12 | Lummus Technology LLC | Apparatus and method for exchanging heat |
| ES2907981T3 (es) | 2016-05-06 | 2022-04-27 | Shanghai De Novo Pharmatech Co Ltd | Derivado de benzazepina, método de preparación, composición farmacéutica y uso del mismo |
| WO2017202704A1 (en) | 2016-05-23 | 2017-11-30 | F. Hoffmann-La Roche Ag | Benzazepine dicarboxamide compounds with tertiary amide function |
| EP3464274B1 (en) | 2016-05-23 | 2020-05-27 | H. Hoffnabb-La Roche Ag | Benzazepine dicarboxamide compounds with secondary amide function |
| EP3468963B1 (en) * | 2016-06-12 | 2021-10-27 | F. Hoffmann-La Roche AG | Dihydropyrimidinyl benzazepine carboxamide compounds |
| EP3574018A4 (en) | 2017-01-27 | 2020-10-07 | Silverback Therapeutics, Inc. | CONJUGATES TARGETING TUMORS AND THEIR METHODS OF USE |
| EP3576782A4 (en) | 2017-02-02 | 2020-12-30 | Silverback Therapeutics, Inc. | COMPOSITIONS OF RECOMBINATION PRODUCT-PEPTIDE AND THEIR METHODS OF USE |
| EP3595668B1 (en) | 2017-03-15 | 2021-07-21 | Silverback Therapeutics, Inc. | Benzazepine compounds, conjugates, and uses thereof |
-
2018
- 2018-03-14 EP EP18767012.0A patent/EP3595668B1/en active Active
- 2018-03-14 MX MX2019010804A patent/MX2019010804A/es unknown
- 2018-03-14 WO PCT/US2018/022510 patent/WO2018170179A1/en unknown
- 2018-03-14 DK DK18767012.0T patent/DK3595668T3/da active
- 2018-03-14 SG SG11201908131R patent/SG11201908131RA/en unknown
- 2018-03-14 SG SG10202110184X patent/SG10202110184XA/en unknown
- 2018-03-14 ES ES18767012T patent/ES2894731T3/es active Active
- 2018-03-14 US US15/774,262 patent/US10239862B2/en active Active
- 2018-03-14 CN CN201880030959.6A patent/CN110612104A/zh active Pending
- 2018-03-14 SG SG10202110182P patent/SG10202110182PA/en unknown
- 2018-03-14 CA CA3055652A patent/CA3055652A1/en active Pending
- 2018-03-14 HU HUE18767012A patent/HUE056427T2/hu unknown
- 2018-03-14 KR KR1020197030167A patent/KR20200031560A/ko unknown
- 2018-03-14 JP JP2020500010A patent/JP2020514419A/ja not_active Ceased
- 2018-03-14 SG SG10202110181R patent/SG10202110181RA/en unknown
- 2018-03-14 AU AU2018236272A patent/AU2018236272B2/en active Active
- 2018-03-14 SG SG10202110183V patent/SG10202110183VA/en unknown
- 2018-03-14 BR BR112019019116A patent/BR112019019116A2/pt unknown
- 2018-03-14 PT PT187670120T patent/PT3595668T/pt unknown
- 2018-03-14 EP EP21179495.3A patent/EP3949969A3/en active Pending
- 2018-05-07 US US15/973,506 patent/US10519131B2/en not_active Expired - Fee Related
-
2019
- 2019-02-12 US US16/274,132 patent/US10442790B2/en active Active
- 2019-02-12 US US16/274,130 patent/US10428045B2/en active Active
- 2019-08-07 US US16/534,903 patent/US20200031798A1/en not_active Abandoned
- 2019-09-11 IL IL269283A patent/IL269283B2/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020514419A5 (sl) | ||
| RU2739612C2 (ru) | Анти-cd123 антитела и их конъюгаты и производные | |
| JP2020534250A (ja) | 抗ｃｄ８抗体およびその使用 | |
| JP2018516243A5 (sl) | ||
| JP2018511628A5 (sl) | ||
| RU2018119296A (ru) | Конъюгаты антитела, содержащие агонисты толл-подобного рецептора | |
| JP2018070648A5 (sl) | ||
| JP2013529059A5 (sl) | ||
| CA2984639A1 (en) | Cd123 antibodies and conjugates thereof | |
| JP2020097579A (ja) | 毒性部分を備える異常細胞拘束性免疫グロブリン | |
| JP2022537151A (ja) | 癌の処置のためのネオアジュバント併用療法での活性化可能抗ｐｄｌ１抗体および抗ｃｔｌａ－４抗体の使用 | |
| JP2017506234A5 (sl) | ||
| JP2017506630A5 (sl) | ||
| RU2016133846A (ru) | Конъюгат лиганд - цитотоксическое лекарственное средство, способ его получения и его применения | |
| AU2017335991B2 (en) | Neutralizing antibodies to the αVβ8 integrin complex for immunotherapy | |
| US20190194309A1 (en) | Macrophage stimulating protein receptor (or ron - recepteur d' origine nantais) antibodies and uses thereof | |
| JP6689847B2 (ja) | がんの治療における使用のための抗−ｃｋ８抗体 | |
| JP2008526256A5 (sl) | ||
| JP2016521262A (ja) | 癌のための併用療法 | |
| JP2021500055A5 (sl) | ||
| JP2020534300A5 (sl) | ||
| ES2737649T3 (es) | Anticuerpos anti-Notch3 | |
| JP2024521629A (ja) | 抗体薬物コンジュゲート、及びその調製方法及びその使用 | |
| EP3678700A1 (en) | Compounds for reducing the viscosity of biological formulations | |
| JP2023527257A (ja) | 抗ｃ－Ｍｅｔ抗体薬物複合体 |